Drug intelligence / Profile preview

erythropoietin + ferric carboxymaltose + vitamin b12 + folic acid

Development stage
Preclinical
Lead developer
Amgen
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous, Intramuscular, Oral
01

Overview

This is a combination therapy consisting of four active components: - Erythropoietin, a glycoprotein hormone that stimulates red blood cell production by acting on erythroid progenitor cells in the bone marrow. - Ferric carboxymaltose, an intravenous iron preparation used to treat iron deficiency anemia by replenishing body iron stores and supporting hemoglobin synthesis. - Vitamin B12 (cyanocobalamin), essential for DNA synthesis and normal maturation of red blood cells. - Folic acid, a B-vitamin required for DNA synthesis and cell division, especially important in rapidly dividing cells such as those in the bone marrow. The combination is primarily used to treat or prevent anemia—especially in populations with high risk or increased requirements (e.g., extremely low birth weight infants, patients with refractory anemia)—by addressing multiple potential deficiencies that can impair effective erythropoiesis. Clinical studies have shown this combined regimen reduces transfusion requirements and improves hematologic parameters compared to monotherapy[1][9].

Brand names
Vitarubin-superconc.Acidum folicum
Other names
Ultra-short-term combination therapyZurich anemia protocolPreoperative treatment of anemia and iron deficiency protocol
02

Targets

DHFR (Dihydrofolate reductase)Erythropoietin Receptor

Beyond the preview

Go deeper on erythropoietin + ferric carboxymaltose + vitamin b12 + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythropoietin + ferric carboxymaltose + vitamin b12 + folic acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call